{
    "clinical_study": {
        "@rank": "36890", 
        "arm_group": [
            {
                "arm_group_label": "LAF237", 
                "arm_group_type": "Experimental", 
                "description": "Vildagliptin 50 mg tablets"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vildagliptin 50 mg matching placebo tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of vildagliptin 50 mg bid\n      add-on therapy to improve overall glycemic control in patients with T2DM inadequately\n      controlled by insulin, with or without concomitant metformin treatment. It was agreed with\n      PMDA to conduct a postmarketing clinical trial to further collect the efficacy and safety\n      data of vildagliptin especially in Japanese patients when it is used on top of insulin."
        }, 
        "brief_title": "Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of T2DM by standard criteria.\n\n          -  HbA1c \u2265 7.0 to \u2264 10% at Visit 1.\n\n          -  Age: \u2265 20 to < 75 years old at Visit 1.\n\n          -  BMI \u2265 20 to \u2264 35 kg/m2 at Visit 1.\n\n        Exclusion Criteria:\n\n          -  FPG \u2265 270 mg/dL (\u226515 mmol/L) at Visit 1.\n\n          -  Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or\n             secondary forms of diabetes.\n\n          -  Significant heart diseases\n\n          -  Hepatic disorder\n\n        Other protocol defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "152", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002221", 
            "org_study_id": "CLAF237A1405"
        }, 
        "intervention": [
            {
                "arm_group_label": "LAF237", 
                "description": "Corresponds to vildagliptin 50 mg twice daily", 
                "intervention_name": "LAF237 50 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo of vildagliptin 50 mg twice daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vildagliptin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Funabashi-city", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "274-0805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "810-8798"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukutsu-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "811-3217"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitakyushu-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "800-0295"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ibusuki-city", 
                        "country": "Japan", 
                        "state": "Kagoshima", 
                        "zip": "891-0401"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-city", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "221-0802"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto-city", 
                        "country": "Japan", 
                        "state": "Kumamoto", 
                        "zip": "861-8520"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto-city", 
                        "country": "Japan", 
                        "state": "Kyoto", 
                        "zip": "615-0035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hirakata-City", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "573-0153"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "534-0021"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Takatsuki-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "569-1096"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ageo-city", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "362-8588"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sayama-city", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "350-1305"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokorozawa-city", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "359-1161"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "101-0024"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "104-0061"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nerima-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "177-0041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nerima-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "177-0051"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ota-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "144-0051"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HbA1c will be performed on a blood sample obtained and measured by HPLC performed at a central laboratory.", 
            "measure": "Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002221"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Responder rates will be analyzed in categories: a.Endpoint HbA1c \u2264 6.5% b.Endpoint HbA1c < 7% c.Endpoint HbA1c < 7% in patients with baseline HbA1c \u2264 8% d.HbA1c reduction from baseline at endpoint \u2265 1% e.HbA1c reduction from baseline at endpoint \u2265 0.5%", 
                "measure": "Percentage of patients meeting Responder rates in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at 12 weeks"
            }, 
            {
                "description": "FPG will be performed on a blood sample obtained and analyzed at a central laboratory.", 
                "measure": "Change from baseline in Fasting plasma glucose (FPG) at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 12 weeks"
            }, 
            {
                "description": "symptoms consistent with hypoglycemia and confirmed by plasma glucose < 56 mg/dL", 
                "measure": "Number of participants with hypoglycemia and sever hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The occurrence of adverse events will be sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, vital sign, or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.", 
                "measure": "Number of patients with adverse events, serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}